Maravai LifeSciences Holdings, Inc.
MRVI Healthcare Biotechnology
Maravai LifeSciences Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $185.7 million, down 28.3% from fiscal 2024. In the quarter to June 2026, revenue grew 8.53%, EPS grew 70.4%, free cash flow grew 127.6% and total debt fell 45.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) EV/Sales
As of 16 October 2026, Maravai LifeSciences Holdings, Inc. (MRVI) trades at a EV/Sales of 5.3×. Over the past ten years it has ranged from 1.2× (April 2025) to 37.0× (December 2020); the current reading is higher than 77% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.1× | 5.95% |
| FY2024 | 2.9× | (3.12%) |
| FY2023 | 3.0× | 56.79% |
| FY2022 | 1.9× | (67.94%) |
| FY2021 | 6.0× | 14.32% |
| FY2020 | 5.2× | (85.37%) |
| FY2019 | 35.8× | 0.00% |
| FY2018 | 35.8× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 4.9× | 94.50% |
| Mar 2026 | 2.5× | (17.94%) |
| Dec 2025 | 3.1× | 20.20% |
| Sep 2025 | 2.6× | 40.55% |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MLYS Mineralys Therapeutics, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | 1.0× |
| VIR Vir Biotechnology, Inc. compare | 3.7× |
| MRVI Maravai LifeSciences Holdings, Inc. | 5.3× |
| URGN Urogen Pharma compare | 9.7× |
| XNCR Xencor, Inc. compare | 13.4× |
| PVLA Palvella Therapeutics, Inc. compare | 35.6× |
| ZYME Zymeworks Inc. compare | 42.0× |
| MESO Mesoblast Limited compare | 137× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)